PVLAPALVELLA THERAPEUTICS, INC.vs its industry peers
A metric-by-metric comparison of PALVELLA THERAPEUTICS, INC. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PVLAThis | $2.2B#8 | — | 10.2x#12 | 51.6x#9 | 65.3%#2 | -139.3%#13 | -90.2%#7 | -19.2%#6 | — | — | 99.0%#4 | — |
| MBX | $2.7B#1 | — | 6.5x#11 | — | — | -40.5%#11 | — | -21.2%#7 | — | — | 166.7%#1 | — |
| RCUS | $2.4B#2 | — | 5.2x#7 | 73.0x#10 | -35.3%#11 | -24.7%#10 | -1169.7%#10 | -76.1%#12 | -93.0%#9 | — | -7.0%#11 | — |
| BHVN | $2.4B#3 | — | — | — | — | 12.7%#6 | — | — | — | — | 5.1%#10 | — |
| PBH | $2.3B#4 | 13.9x#2 | 1.2x#2 | 2.2x#3 | -4.3%#9 | -11.3%#9 | 28.4%#1 | 9.9%#2 | 5.9%#3 | 4#1 | -18.2%#13 | — |
| IMNM | $2.3B#5 | — | 4.4x#5 | 332.7x#11 | -23.2%#10 | 27.5%#5 | -3228.8%#11 | -40.4%#8 | -72.8%#7 | — | 19.4%#8 | — |
| XNCR | $2.3B#6 | — | 4.5x#6 | 18.2x#6 | 13.7%#6 | 60.5%#2 | -141.4%#8 | -18.3%#5 | -31.5%#5 | — | 120.4%#2 | — |
| VERA | $2.2B#7 | — | 5.4x#9 | — | — | -96.9%#12 | — | -73.5%#11 | -72.7%#6 | — | 18.5%#9 | — |
| PRGO | $2.2B#9 | — | 0.9x#1 | 0.5x#1 | -2.8%#8 | -729.7%#15 | -26.4%#4 | -56.7%#10 | -20.9%#4 | 4#1 | -18.0%#12 | 7.3%#1 |
| HRMY | $2.2B#10 | 12.0x#1 | 2.2x#4 | 2.5x#4 | 21.5%#5 | 9.1%#8 | 24.0%#2 | 15.9%#1 | 25.5%#1 | 4#1 | 26.2%#7 | — |
| ZYME | $2.1B#11 | — | 26.6x#13 | 20.2x#7 | 38.9%#4 | 33.9%#3 | -87.3%#6 | -100.9%#13 | — | — | 59.5%#5 | — |
| SEPN | $2.0B#12 | — | 5.3x#8 | 44.4x#8 | 4174.5%#1 | 31.9%#4 | -148.6%#9 | -12.6%#3 | — | — | 118.1%#3 | — |
| TRVI | $2.0B#13 | — | 6.1x#10 | — | — | 10.7%#7 | — | -13.3%#4 | — | — | 29.6%#6 | — |
| SRPT | $2.0B#14 | — | 1.3x#3 | 1.1x#2 | 4.3%#7 | -403.3%#14 | -37.5%#5 | -46.7%#9 | -73.0%#8 | — | -24.2%#14 | — |
| BRVE | $1.9B#15 | — | — | — | — | — | — | — | — | — | — | — |
| XERS | $1.9B#16 | — | — | 6.5x#5 | 43.7%#3 | 101.0%#1 | 8.5%#3 | — | 20.6%#2 | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-11-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice